

# Joseph I Clark

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2612452/publications.pdf>

Version: 2024-02-01

45  
papers

15,634  
citations

471061

17  
h-index

395343

33  
g-index

47  
all docs

47  
docs citations

47  
times ranked

19742  
citing authors

#	ARTICLE	IF	CITATIONS
1	Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. <i>New England Journal of Medicine</i> , 2010, 363, 711-723.	13.9	13,065
2	Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 133-141.	0.8	746
3	Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. <i>JAMA Oncology</i> , 2016, 2, 234.	3.4	534
4	Adjuvant High-Dose Bolus Interleukin-2 for Patients With High-Risk Renal Cell Carcinoma: A Cytokine Working Group Randomized Trial. <i>Journal of Clinical Oncology</i> , 2003, 21, 3133-3140.	0.8	307
5	The High-Dose Aldesleukin "Select" Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2015, 21, 561-568.	3.2	133
6	Multi-Institutional Study of the Angiogenesis Inhibitor TNP-470 in Metastatic Renal Carcinoma. <i>Journal of Clinical Oncology</i> , 1999, 17, 2541-2541.	0.8	124
7	Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition. , 2019, 7, 49.		102
8	Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1533-1544.	2.0	89
9	An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. , 2018, 6, 44.		59
10	Phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinoma. <i>Cancer</i> , 2001, 92, 2334-2340.	2.0	51
11	Randomized Phase II Trial of Sequential Chemotherapy in Advanced Non-Small Cell Lung Cancer (SWOG) Tj ETQq1 1 0.784314 rgBT / Ov 3.2 49	0.784314	49
12	Kidney Cancer: The Cytokine Working Group Experience (1986 -2001): Part II: Management of IL-2 Toxicity and Studies with Other Cytokines. <i>Medical Oncology</i> , 2001, 18, 209-220.	1.2	40
13	Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIM SM. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 31-41.e4.	0.9	31
14	Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry. , 2017, 5, 102.		31
15	Role of Imaging in Renal Cell Carcinoma: A Multidisciplinary Perspective. <i>Radiographics</i> , 2021, 41, 1387-1407.	1.4	30
16	The PARADIGM trial: A phase III study comparing sequential therapy (ST) to concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer (LANHC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 5501-5501.	0.8	30
17	Response to paclitaxel and carboplatin in metastatic salivary gland cancer: A case report. <i>Head and Neck</i> , 2002, 24, 406-410.	0.9	28
18	Kidney Cancer: The Cytokine Working Group Experience (1986 -2001): Part I. IL-2-Based Clinical Trials. <i>Medical Oncology</i> , 2001, 18, 197-208.	1.2	27

#	ARTICLE	IF	CITATIONS
19	Pilot study of sequential vinorelbine and cisplatin followed by docetaxel for selected IIIB and stage IV non-small cell lung cancer. <i>Lung Cancer</i> , 2001, 34, 271-277.	0.9	24
20	Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. <i>Cancer</i> , 2010, 116, 424-431.	2.0	20
21	Robust Differences in p16-Dependent Oropharyngeal Squamous Cell Carcinoma Distant Metastasis. <i>Otolaryngology - Head and Neck Surgery</i> , 2015, 153, 209-217.	1.1	15
22	A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma. , 2018, 6, 76.		14
23	Phase III AXIS trial for second-line metastatic renal cell carcinoma (mRCC): Effect of prior first-line treatment duration and axitinib dose titration on axitinib efficacy.. <i>Journal of Clinical Oncology</i> , 2012, 30, 354-354.	0.8	12
24	High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma. <i>Frontiers in Oncology</i> , 2019, 9, 1483.	1.3	10
25	New therapeutic strategies for the treatment and prevention of head and neck cancer. <i>Expert Opinion on Investigational Drugs</i> , 2000, 9, 2855-2872.	1.9	9
26	Phase I pilot study of oxaliplatin, infusional 5-FU, and cetuximab in recurrent or metastatic head and neck cancer. <i>Medical Oncology</i> , 2013, 30, 358.	1.2	8
27	Combination Trimodality Therapy Using Vismodegib for Basal Cell Carcinoma of the Face. <i>Case Reports in Oncological Medicine</i> , 2015, 2015, 1-6.	0.2	8
28	Phase I/II Trial of Outpatient PEG-interferon With Interleukin-2 in Advanced Renal Cell Carcinoma: A Cytokine Working Group Study. <i>Journal of Immunotherapy</i> , 2007, 30, 839-846.	1.2	6
29	Long-term (LT) disease-free survival (DFS) of melanoma (MM) and renal cell cancer (RCC) patients following high-dose interleukin-2 (HD IL2).. <i>Journal of Clinical Oncology</i> , 2017, 35, e21005-e21005.	0.8	5
30	Phase I Adjuvant Radiation With Docetaxel in High-Risk Head and Neck Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009, 32, 396-400.	0.6	4
31	Combined radio-immunotherapy leads to complete clinical regression of stage IV Merkel cell carcinoma. <i>BMJ Case Reports</i> , 2019, 12, e230518.	0.2	4
32	Pdl-1/pdl-3 (programmed death ligand-1/3) tissue expression and response to treatment with IL2 and antiangiogenic therapies.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4521-4521.	0.8	4
33	Safety and efficacy of ipilimumab in melanoma patients who received prior immunotherapy on phase III study MDX010-020.. <i>Journal of Clinical Oncology</i> , 2013, 31, 9050-9050.	0.8	3
34	Vaccine therapy of malignant melanoma. <i>Clinical and Applied Immunology Reviews</i> , 2006, 6, 217-230.	0.4	2
35	Ipilimumab for the treatment of melanoma. <i>Melanoma Management</i> , 2015, 2, 33-39.	0.1	2
36	Rhabdomyolysis during high dose interleukin-2 treatment of metastatic melanoma after sequential immunotherapies: a case report. , 2018, 6, 53.		2

#	ARTICLE	IF	CITATIONS
37	A Prospective Analysis of High-Dose Interleukin-2 (HD IL-2) following PD-1 inhibitor therapy in patients with metastatic melanoma and renal cell carcinoma.. Journal of Clinical Oncology, 2016, 34, e21006-e21006.	0.8	2
38	Interleukin-2 and Cancer Therapy. , 2007, , 307-316.		1
39	Durability of responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2 (HD IL-2).. Journal of Clinical Oncology, 2016, 34, 511-511.	0.8	1
40	Phase I pilot study of oxaliplatin, infusional 5-FU, and cetuximab in recurrent or metastatic head and neck cancer.. Journal of Clinical Oncology, 2012, 30, e16027-e16027.	0.8	0
41	Experience with IL-2 in metastatic renal cell carcinoma after treatment with one or more targeted therapies.. Journal of Clinical Oncology, 2016, 34, 622-622.	0.8	0
42	Update on the overall survival of patients with metastatic melanoma treated with immune checkpoint blockade following initial treatment with HD IL-2.. Journal of Clinical Oncology, 2016, 34, e21039-e21039.	0.8	0
43	Extension of overall survival in patients with metastatic renal cell carcinoma who received HD IL-2 followed by targeted therapy and/or immune checkpoint blockade from the PROCLAIM registry.. Journal of Clinical Oncology, 2016, 34, 4548-4548.	0.8	0
44	Efficacy and tolerability of high dose interleukin-2 (HD IL-2) after disease progression on targeted therapy (TT) for metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2016, 34, e16064-e16064.	0.8	0
45	Association of improved survival (OS) and tumor control (TC) with interleukin-2 (IL2) with development of immune-related events (IREs): Data from the PROCLAIMSM registry.. Journal of Clinical Oncology, 2017, 35, 9528-9528.	0.8	0